{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T06:30:01Z","timestamp":1774852201456,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ejphar.2015.09.028","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T22:42:01Z","timestamp":1443566521000},"page":"25-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets"],"prefix":"10.1016","volume":"766","author":[{"given":"Shin-ichi","family":"Uchida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Soshiroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Okita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kawai-Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2015.09.028_bib1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2015.09.028_bib2","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1523\/JNEUROSCI.20-15-05848.2000","article-title":"Rescue of locomotor impairment in dopamine D2 receptor deficient mice by an adenosine A2A receptor antagonist","volume":"20","author":"Aoyama","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2015.09.028_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/13543784.2014.869209","article-title":"Dopamine receptor agonists for Parkinson\u2019s disease","volume":"23","author":"Blandini","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2015.09.028_bib4","doi-asserted-by":"crossref","first-page":"E3609","DOI":"10.1073\/pnas.1507704112","article-title":"Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer","volume":"112","author":"Bonaventura","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2015.09.028_bib5","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S1353-8020(09)70835-1","article-title":"Role of dopamine receptor agonists in the treatment of early Parkinson\u2019s disease","volume":"Suppl 4","author":"Bonuccelli","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ejphar.2015.09.028_bib6","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1073\/pnas.98.4.1970","article-title":"The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular response in as revealed by A2A and D2 receptor knockout mice","volume":"98","author":"Chen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2015.09.028_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1242\/dmm.018143","article-title":"Untangling dopamine-adenosine receptor\u2013receptor assembly in experimental parkinsonism in rats","volume":"8","author":"Fern\u00e1ndez-Due\u00f1as","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ejphar.2015.09.028_bib8","article-title":"Allosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramer","author":"Ferr\u00e9","year":"2015","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.ejphar.2015.09.028_bib9","first-page":"345","article-title":"Adenosine receptors and Parkinson\u2019s disease. Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum","volume":"86","author":"Fuxe","year":"2001","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.ejphar.2015.09.028_bib10","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/mds.22095","article-title":"Study of istradefylline in patients with Parkinson\u2019s disease on levodopa with motor fluctuations","volume":"23","author":"Hauser","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2015.09.028_bib11","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/aps.2013.87","article-title":"Modulation of A2a receptor antagonist on D2 receptor internalization and ERK phosphorylation","volume":"34","author":"Huang","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2015.09.028_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ana.410430415","article-title":"Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys","volume":"43","author":"Kanda","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2015.09.028_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0014-2999(00)00745-7","article-title":"Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-parkinsonian rats","volume":"408","author":"Koga","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.09.028_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.21315","article-title":"Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201c time in Parkinson\u2019s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)","volume":"63","author":"LeWitt","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2015.09.028_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WNF.0b013e31825c034a","article-title":"A systematic review of catechol-o-methyltransferase inhibitors: efficacy and safety in clinical practice","volume":"35","author":"Marsala","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2015.09.028_bib16","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/mds.25418","article-title":"Adenosine A2A receptor antagonist istradefylline reduces daily off time in Parkinson\u2019s disease","volume":"28","author":"Mizuno","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2015.09.028_bib17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1353-8020(01)00024-4","article-title":"Motor fluctuations and dyskinesia in Parkinson\u2019s disease","volume":"8","author":"Nutt","year":"2001","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ejphar.2015.09.028_bib18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/11537810-000000000-00000","article-title":"Dopamine receptor agonists for the treatment of early or advanced Parkinson\u2019s disease","volume":"24","author":"Perez-Lloret","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2015.09.028_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/157488612800492726","article-title":"Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson\u2019s Disease and other disorders","volume":"7","author":"Raja","year":"2012","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.ejphar.2015.09.028_bib20","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11596310-000000000-00000","article-title":"Monoamine oxidase B inhibitors for the treatment of Parkinson\u2019s disease: a review of symptomatic and potential disease-modifying effects","volume":"25","author":"Schapira","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2015.09.028_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","article-title":"Targeting adenosine A2A receptors in Parkinson\u2019s disease","volume":"29","author":"Schwarzschild","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ejphar.2015.09.028_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.870120616","article-title":"Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets","volume":"12","author":"Smith","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2015.09.028_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/mds.22960","article-title":"Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets","volume":"25","author":"Tayarani-Binazir","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2015.09.028_bib24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2014.11.038","article-title":"The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets","volume":"747","author":"Uchida","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.09.028_bib25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1254\/jphs.13250FP","article-title":"The adenosine A2A receptor antagonist, istradefylline enhances the motor response of l-DOPA without worsening dyskinesia in MPTP-treated common marmosets","volume":"124","author":"Uchida","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2015.09.028_bib26","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/mds.25364","article-title":"Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease","volume":"28","author":"Warren Olanow","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2015.09.028_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000341996","article-title":"Impulse control and related disorders in Parkinson\u2019s disease","volume":"11","author":"Weintraub","year":"2013","journal-title":"Neurodegener. Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915302600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915302600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T03:17:50Z","timestamp":1567221470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915302600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":27,"alternative-id":["S0014299915302600"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.09.028","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}